GlassScriptPhysician profile
Ronald L Leon
NPI 1467418830
$140,250.85
in general payments reported to CMS, 2019-2025
25 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $5,634 · 2021: $5,871 · 2022: $27K · 2023: $24K · 2024: $18K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Food and Beverage: $11K · Travel and Lodging: $7,660 · Consulting Fee: $6,230 · Education: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,590.00 |
| Food and Beverage | $11,040.93 |
| Travel and Lodging | $7,659.94 |
| Consulting Fee | $6,230.00 |
| Education | $478.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $60,797.48 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $28,822.29 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $24,235.90 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Allergan, INC. | $14,862.16 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $2,162.11 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,826.78 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $1,567.99 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $1,256.48 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $999.96 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $991.10 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $873.72 | 2020-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $626.11 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $450.51 | 2023-2025 | Auvelity |
| Indivior INC. | $271.57 | 2019-2024 | Perseris |
| Eisai INC. | $119.40 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $91.98 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $59.16 | 2019-2022 | |
| Shire North American Group INC | $46.91 | 2019 | |
| Bausch Health US, LLC | $39.91 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $36.72 | 2019 | |
| Merck Sharp & Dohme LLC | $31.43 | 2022-2023 | Belsomra |
| Owp Pharmaceuticals, INC. | $25.97 | 2021 | |
| Luye Pharma (USA) LTD. | $22.32 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $17.32 | 2020 | |
| Adlon Therapeutics L.P. | $15.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.